Age-specific efficacy of biologics in severe asthma: a pediatric perspective
Beatrice Andrenacci, Francesca Calciano, Barbara Madini, Alessia Rocchi, Daniele Giovanni Ghiglioni, Laura Maffeis, Maria Francesca Patria, Amelia Licari, Gian Luigi Marseglia · 2026
Read Age-specific efficacy of biologics in severe asthma: a pediatric perspective by Beatrice Andrenacci, Francesca Calciano, Barbara Madini, Alessia Rocchi, Daniele Giovanni Ghiglioni, Laura Maffeis, Maria Francesca Patria, Amelia Licari, Gian Luigi Marseglia (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13219044.txt.
Description
Beatrice Andrenacci and co-authors review biologic drugs for severe child asthma by age in a 2026 paper. Severe asthma in kids is rare but heavy, and standard drugs often fail it. Biologics changed adult care over two decades, yet trials mostly skipped children.
Young bodies answer drugs in their own ways, so adult proof cannot just be scaled down. The review sums child specific proof for Europe licensed biologics, with safety beside benefit. Open fronts span early preventive use, fresh delivery routes, drug pairs, and a shared sense of remission. Child fit outcome marks are still owed.
Catalog record
| CREATOR | Beatrice Andrenacci, Francesca Calciano, Barbara Madini, Alessia Rocchi, Daniele Giovanni Ghiglioni, Laura Maffeis, Maria Francesca Patria, Amelia Licari, Gian Luigi Marseglia |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |